EGRX Stock Price, Chart, Stats & News
Eagle Pharmaceuticals, Inc. (EGRX) does not currently pay a dividend.
EGRX chart
Fundamentals
Gross margin | 70.01% |
Operating margin | 25.57% |
Pretax margin | 19.40% |
Net margin | 11.26% |
Effective tax rate | 41.98% |
ROA | 8.78% |
ROE | 17.39% |
D/E | 0.29x |
Interest coverage ratio | 20.01x |
EGRX valuation
P/E | 3.94x |
P/S | 0.01x |
P/B | 0.02x |
P/CF | 0.14x |
P/FCF | 0.14x |
P/OCF | 0.14x |
PEG | 0.00x |
EV multiple | -0.10x |
About
Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on manufacturing, developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company’s product portfolio offers RYANODEX for malignant hyperthermia; and BELRAPZO and BENDEKA for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin’s lymphoma. It also produces PEMFEXY, a ready-to-dilute liquid form of pemetrexed injection, indicated in combination with cisplatin for the initial treatment of patients with malignant pleural mesothelioma and non-small cell lung cancer; BARHEMSYS, a selective dopamine-2 (D2) and dopamine-3 (D3) receptor antagonist indicated in adults for prevention of postoperative nausea and vomiting (PONV); BYFAVO, a benzodiazepine indicated for the induction and maintenance of procedural sedation in adults.
Similar securities
Based on sector and market capitalization
